Page last updated: 2024-11-12

glycoprotein e2, hepatitis c virus

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycoprotein E2, Hepatitis C virus: RN refers to quasispecies 4E; amino acid sequence known; caution: HCV also stands for hog cholera virus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16131053
MeSH IDM0240444

Synonyms (10)

Synonym
e2 glycoprotein, hepatitis c virus
hcv e2 protein
hcv envelope 2 protein
envelope 2 protein, hepatitis c virus
157184-61-7
envelope 2 protein, hcv
e2 protein, hcv
glycoprotein e2, hepatitis c virus
hepatitis c virus envelope 2 protein
DTXSID70166223

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Transmembrane (TM) peptides often induce toxic effects when expressed in bacteria, probably due to membrane destabilization."( Overcoming the toxicity of membrane peptide expression in bacteria by upstream insertion of Asp-Pro sequence.
Falson, P; Lethias, C; Montigny, C; Penin, F, 2004
)
0.32
"These results suggest that targeting envelope HMGs is a promising therapeutic approach against HCV infection, and AvFc may provide a safe and efficacious means to prevent recurrent infection upon liver transplantation in HCV-related end-stage liver disease patients."( Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model.
Dent, M; Dubuisson, J; Hamorsky, K; Matoba, N; Miyata, Y; Morikawa, Y; Vausselin, T, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" Stepwise multiple logistic regression analysis of the factors (age, gender, viral load, cirrhosis rate, IFN dosage and amino acid substitutions) revealed that the mutation in NS5A-ISDR (>/= 4 vs < 4) was the only independent variable of treatment outcome."( Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
Changchien, CS; Chen, TM; Chen, WJ; Hu, TH; Hung, CH; Lee, CM; Lee, JF; Lu, SN; Tung, HD; Wang, JH, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (872)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's120 (13.76)18.2507
2000's427 (48.97)29.6817
2010's297 (34.06)24.3611
2020's28 (3.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.87 (24.57)
Research Supply Index6.81 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (1.79%)5.53%
Reviews53 (5.94%)6.00%
Case Studies9 (1.01%)4.05%
Observational1 (0.11%)0.25%
Other813 (91.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]